Trastuzumab Deruxtecan for Breast Cancer NEJM

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line trastuzumab Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast trastuzumab The results of this trial indicate that trastuzumab is active as a single agent and produces durable objective responses in women with HER2-overexpressing

trastuzumab Trastuzumab belongs to class of monoclonal antibody It binds selectively to a protein called human epidermal growth factor receptor 2